New pill tested for Tough-to-Treat leukemias
NCT ID NCT04278768
Summary
This study is testing a new oral drug called CA-4948 (emavusertib) for adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that has come back or hasn't responded to prior treatments. The main goals are to find the safest and most effective dose and to see if the drug can help control these cancers. The trial is currently suspended and not enrolling new participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
APHP - Hopital Saint Louis
Paris, 75475, France
-
APHP - Sorbonne Universite
Paris, 75012, France
-
Albert Einstein Medical College
The Bronx, New York, 10461, United States
-
Azienda Ospedaliera Santa Croce e Carle
Cuneo, Italy
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Edith Wolfson Medical Center
Holon, 5822012, Israel
-
Hadassah University MC
Jerusalem, 9112001, Israel
-
Hospital Universitario Virgen del Rocio
Seville, Spain
-
Hospital Universitaro del a Princesa
Madrid, 28006, Spain
-
Hospital de la Santa Creu I Sant Pau (Neuvo Hospital)
Barcelona, Spain
-
Instituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Meldola, Italy
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Klinikum rechts der Isar der Technischen Universitat Munchen
München, 81675, Germany
-
MD Anderson Cancer Center Madrid
Madrid, Spain
-
Marien Hospital Dusseldorf; Klinik fur Onkologie und Hamatologie, Palliativmedizin
Düsseldorf, 40479, Germany
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Northwestern Memorial Hospital
Chicago, Illinois, 60611, United States
-
Novant Health Hematology - Forsyth
Winston-Salem, North Carolina, 27103, United States
-
Oncology Hematology West, PC dba Nebraska Cancer Specialists
Omaha, Nebraska, 68130, United States
-
Service d'hématologie clinique CHU de Nice
Nice, 6200, France
-
Soroka University MC
Beersheba, 84100, Israel
-
The Ohio State University Wexner Medical Center - James Cancer Hospital
Columbus, Ohio, 43210, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Universitatsklinikum Leipzig; Medizinische Klinik und Poliklinik I
Leipzig, 04103, Germany
-
Universitatsklinikum Munster
Münster, 48149, Germany
-
University Hospital in Krakow
Krakow, 31 501, Poland
-
University of Chicago Medical Center
Chicago, Illinois, 60637, United States
-
University of Rochester Medical Center
Rochester, New York, 14642, United States
-
Universitätsklinikum Hamburg-Eppendorf (UKE)
Hamburg, 20246, Germany
-
Uniwersyteckie Centrum Kliniczne Osrodek Badan Klinicznych Wczesnych Faz
Gdansk, 80-214, Poland
-
Vseobecna Fakultni nemocnice v Praze
Prague, 12 808, Czechia
-
Winship Cancer Institute
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.